BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week.
Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph Kern, MD, Brainstorm’s chief operating officer and chief medical officer, in an interview to ALS News Today days before the Dec. 8–10 symposium.
NurOwn is an autologous adult stem cell therapy technology that uses a patient’s own stem cells — specifically, bone marrow-derived mesenchymal stem cells (MSC) — and differentiates them into neuron-supporting cells.
Its cells work by secreting nerve-growth factors known to protect existing motor neurons and promote motor neuron growth, with the potential of helping to re-establish nerve-muscle interaction.
More at: https://alsnewstoday.com/2017/12/12/brainstorm-cmo-talks-in-interview-about-nurown-and-potential-as-therapy-for-als-with-rapid-progression/
